The Aeon Herald / HISTORICAL EDITION
Salk Vaccine Trial Reports Protection Against Polio
The announcement at Ann Arbor brings hope after a vast field trial involving American schoolchildren.
ANN ARBOR, Mich., April 13.—A major field trial has found the Salk vaccine effective against paralytic poliomyelitis, giving parents and physicians new grounds for hope against a disease whose summer outbreaks have caused widespread fear. The results were announced yesterday by Dr. Thomas Francis Jr. at the University of Michigan.
The vaccine developed by Dr. Jonas Salk uses killed poliovirus and is administered by injection. The trial's great scale has been essential to judging whether vaccinated children were protected more often than comparable children who did not receive it. The report concerns measured protection, not a promise that every vaccinated child is beyond risk.
Federal licensing has opened the way toward wider use. Production, inspection and the orderly provision of doses now become matters of immediate public importance. An encouraging result must be followed by careful manufacture and administration.
For families acquainted with isolation wards, braces and iron lungs, the announcement is more than a scientific occasion. It offers the possibility that a dreaded seasonal uncertainty can be reduced by prevention. That possibility deserves confidence disciplined by care.
Sources & further reading
- Polio Vaccine Evaluation Results: First press release— University of Michigan Information and News Service; Thomas Francis Jr.; April 12, 1955, 10:20 am EST.
- History of polio vaccination— World Health Organization; undated institutional chronology.

